First: cholesterol and particles are not the same thing
Cholesterol travels through the bloodstream inside particles called lipoproteins. LDL-C estimates the amount of cholesterol carried inside LDL particles; it does not directly count how many atherogenic particles are present.
What does non-HDL cholesterol show?
Non-HDL-C is calculated by subtracting HDL-C from total cholesterol. It includes cholesterol carried by LDL, remnant particles, lipoprotein(a), and other ApoB-containing particles. It can be particularly helpful when triglycerides are elevated.
What does ApoB show?
Each major atherogenic particle carries one molecule of apolipoprotein B. ApoB therefore approximates the total number of these particles. Two people with a similar LDL-C can have different numbers of particles and different ApoB values.
When can results be discordant?
Discordance is more common with high triglycerides, diabetes, obesity, and metabolic syndrome. LDL-C may appear acceptable while non-HDL-C or ApoB suggests a greater atherogenic particle burden.
Which result is best?
There is no single answer for every person. LDL-C remains a central treatment marker. The 2026 ACC/AHA dyslipidemia guideline notes that ApoB can improve risk assessment, especially with triglycerides above 200 mg/dL, diabetes, or a very low achieved LDL-C. Targets and treatment decisions depend on overall cardiovascular risk—not only the laboratory reference interval.